Small molecule · Inhibitor of RET proto-oncogene (RET) · developed by Rigel Pharms
Pralsetinib is an oral kinase inhibitor that potently blocks wild-type RET and oncogenic RET fusions and mutations, suppressing the signaling that drives uncontrolled tumor cell proliferation. It also inhibits several other kinases at higher concentrations. It is studied in non-small cell lung cancer, thyroid cancer, and solid tumor malignancies.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 30, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07704658 | Phase 4 | NSCLC (Non-small Cell Lung Cancer) | Recruiting | RIGL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced MalignanciesNSCLC (Non-small Cell Lung Cancer)Solid Tumor MalignanciesThyroid Cancer
Updated Nov 1, 2026. Something wrong or missing? Report it on the RIGL page.
See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RIGL catalysts and pipeline →